Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.67 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.67 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
| ▸ | BRAF | P15056 | 13/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745979 | 0.84 | PDE10A (0.66) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15733493 | 0.83 | PDE10A (0.68) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15022253 | 0.83 | PDE10A (0.61) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15022105 | 0.82 | MAP4K4 (0.70) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15022080 | 0.82 | PDE10A (0.49) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15022077 | 0.82 | PDE10A (0.63) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL5258392 | 0.81 | MAPK13 (0.74) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15022104 | 0.81 | MAPK13 (0.54) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15022320 | 0.81 | MAPK13 (0.57) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL5257540 | 0.80 | CSNK1D (1.00) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | CHRNA10, ATXN10, SCN10A | MAPK13 2559/4885CSNK1D 2512/4885CSNK1E 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.